Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • AUD/USD

    0.6528
    +0.0028 (+0.43%)
     
  • OIL

    83.24
    +0.43 (+0.52%)
     
  • GOLD

    2,337.70
    -0.70 (-0.03%)
     
  • Bitcoin AUD

    98,009.99
    -4,268.11 (-4.17%)
     
  • CMC Crypto 200

    1,365.21
    -17.37 (-1.26%)
     
  • AUD/EUR

    0.6084
    +0.0013 (+0.22%)
     
  • AUD/NZD

    1.0948
    +0.0006 (+0.06%)
     
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,093.44
    +53.06 (+0.66%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,019.62
    -69.08 (-0.38%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Those who invested in Universal Biosensors (ASX:UBI) three years ago are up 140%

Some Universal Biosensors, Inc. (ASX:UBI) shareholders are probably rather concerned to see the share price fall 49% over the last three months. But that doesn't undermine the rather lovely longer-term return, if you measure over the last three years. In fact, the share price is up a full 140% compared to three years ago. After a run like that some may not be surprised to see prices moderate. The fundamental business performance will ultimately dictate whether the top is in, or if this is a stellar buying opportunity.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

See our latest analysis for Universal Biosensors

Because Universal Biosensors made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

ADVERTISEMENT

Universal Biosensors actually saw its revenue drop by 100% per year over three years. So the share price gain of 34% per year is quite surprising. It's a good reminder that expectations about the future, not the past history, always impact share prices.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

While the broader market gained around 4.6% in the last year, Universal Biosensors shareholders lost 29%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 1.8% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Universal Biosensors better, we need to consider many other factors. For instance, we've identified 4 warning signs for Universal Biosensors that you should be aware of.

We will like Universal Biosensors better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.